Paper Details

  1. Home
  2. Paper Details

Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?

Author: BrandtMaximilian P, HeckMatthias M, HeideggerIsabel

Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Three new androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) have been approved by the Food and Drug Administration for the treatment of nonmetastatic castration-resistant prostate cancer. These drugs have shown good clinical efficacy with tolerable side effects in large phase III trials. This review discusses the use of these new treatment options, focusing on patient selection and the impact of new imaging modalities like prostate-specific membrane antigen-positron-emission tomography.
Paper Details　
Original Abstract of the Article :
Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer. After proofing their clinical efficacy in large phase III registration trials with go...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.urolonc.2019.11.007

データ提供：米国国立医学図書館（NLM）

Navigating the Treatment Landscape of Non-Metastatic Castration-Resistant Prostate Cancer

The field of [oncology] is constantly seeking new ways to combat [cancer]. This research focuses on [nonmetastatic castration-resistant prostate cancer], exploring the latest advancements in treatment with the advent of three [novel second-generation androgen receptor antagonists]. The authors provide a comprehensive overview of these [treatment options] and discuss their use in [daily routine], highlighting the importance of [patient selection] and the role of [novel sensitive imaging modalities] in detecting this stage of disease.

New Hope for Non-Metastatic Castration-Resistant Prostate Cancer

The development of [novel second-generation androgen receptor antagonists] has significantly changed the treatment landscape for [nonmetastatic castration-resistant prostate cancer]. These drugs have shown [clinical efficacy] in large-scale trials, offering [good compatibilities] and [tolerable side effects]. This represents a major breakthrough in the fight against this type of cancer, much like discovering a hidden oasis in the vast expanse of the desert.

Personalized Treatment and Early Detection: Key Strategies

The study emphasizes the importance of [patient selection] and [early detection] for successful treatment of [nonmetastatic castration-resistant prostate cancer]. The use of [novel sensitive imaging modalities] is crucial for identifying the disease in its early stages, akin to using a compass and a map to navigate the challenging terrain of cancer diagnosis.

Dr.Camel's Conclusion

The research highlights the promising advancements in the treatment of [nonmetastatic castration-resistant prostate cancer], offering hope to patients battling this disease. The focus on [personalized treatment] and [early detection] is a key factor in achieving positive outcomes, much like finding the right path through the desert to reach a destination.

Date :
  1. Date Completed 2021-04-12
  2. Date Revised 2021-04-12
Further Info :

Pubmed ID

31953000

DOI: Digital Object Identifier

10.1016/j.urolonc.2019.11.007

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.